Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial

被引：7

作者：

Richardson, Paul G. ^{[1
]}

Sandhu, Irwindeep ^{[2
]}

Hofmeister, Craig C. ^{[3
]}

Orlowski, Robert Z. ^{[4
]}

White, Darrell ^{[5
,6
]}

Belotti, Angelo ^{[7
]}

Hansen, Charlotte Toftmann ^{[8
]}

Raje, Noopur S. ^{[9
]}

Chow, Tracy T. ^{[10
]}

Zhou, Zehua ^{[10
]}

Civardi, Tiziana ^{[11
]}

Koo, Phillip ^{[10
]}

Zhu, Yue ^{[10
]}

Katz, Jessica ^{[10
]}

Oriol, Albert ^{[12
,13
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Cross Canc Inst, Edmonton, AB, Canada

[3] Winship Canc Inst Emory Univ, Atlanta, GA USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[5] Dalhousie Univ, Halifax, NS, Canada

[6] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[7] ASST Spedali Civili Brescia, Dept Hematol, Brescia, Italy

[8] Odense Univ Hosp, Odense, Denmark

[9] Massachusetts Gen Hosp, Boston, MA USA

[10] Bristol Myers Squibb, Princeton, NJ USA

[11] Bristol Myers Squibb Co, Celgene Int Sarl, Boudry, Switzerland

[12] Hosp Germans Trias i Pujol, Catalan Inst Oncol, Badalona, Spain

[13] Hosp Germans Trias i Pujol, Josep Carreras Inst, Badalona, Spain

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174443

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial
Oriol, Albert
Sandhu, Irwindeep
Raab, Marc
White, Darrell
LeBlanc, Richard
Raje, Noopur
Ocio, Enrique
Perrot, Aurore
Facon, Thierry
Rodriguez, Cesar
Waesch, Ralph
Amatangelo, Michael
Zhou, Zehua
Wang, Yue
Civardi, Tiziana
Koo, Philip
Maciag, Paulo
Zhu, Daniel
Katz, Jessica
Richardson, Paul
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S31 - S31
[2] Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial
Raab, Marc S.
Oriol, Albert
Sandhu, Irwindeep
White, Darrell
Leblanc, Richard
Raje, Noopur
Ocio, Enrique M.
Perrot, Aurore
Facon, Thierry
Rodriguez, Cesar
Waesch, Ralph
Amatangelo, Michael
Zhou, Zehua
Wang, Yue
Civardi, Tiziana
Koo, Phillip
Maciag, Paulo
Zhu, Daniell
Katz, Jessica
Richardson, Paul G.
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 115 - 115
[3] Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results From the CC-92480-MM-002 Trial
Oriol, Albert
Sandhu, Irwindeep
Raab, Marc S.
White, Darrell
LeBlanc, Richard
Raje, Noopur
Ocio, Enrique M.
Perrot, Aurore
Facon, Thierry
Rodriguez, Cesar
Waesch, Ralph
Amatangelo, Michael
Zhou, Zehua
Wang, Yue
Civardi, Tiziana
Koo, Phillip
Maciag, Paulo
Zhu, Daniel
Katz, Jessica
Richardson, Paul G.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S566 - S566
[4] Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial
Orlowski, Robert Z.
Bahlis, Nizar J.
Quach, Hang
Popat, Rakesh
Lonial, Sagar
Kim, Kihyun
Mateos, Maria-Victoria
Pawlyn, Charlotte
Ramasamy, Karthik
Martinez-Lopez, Joaquin
Casas-Aviles, Ignacio
Spirli, Alessia
Gong, Jing
Amatangelo, Michael
Katz, Jessica
Maciag, Paulo
Peluso, Teresa
Richardson, Paul G.
Trudel, Suzanne
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S492 - S493
[5] Mezigdomide (MEZI; CC-92480) in Combination with Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Raab, M. S.
Richardson, P. G.
Sandhu, I
Oriol, A.
White, D.
LeBlanc, R.
Perrot, A.
Ocio, E. M.
Raje, N.
Hansen, C. Toftmann
Zhou, Z.
Civardi, T.
Katz, J.
Peluso, T.
Dimopoulos, M.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 56 - 56
[6] Mezigdomide (MEZI) monotherapy in relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-001 trial
Goldsmith, Scott
Oriol, Albert
Anttila, Pekka
Bahlis, Nizar
Berdeja, Jesus
Cowan, Andrew
Dimopoulos, Meletios
Foster, Laahn
Hillengass, Jens
Louzada, Martha
Wu, Ka Lung
Chow, Tracy
Chen, Wencong
Wang, Yue
Spirli, Alessia
Koo, Phillip
Maciag, Paulo
Zhu, Daniel
Katz, Jessica
Richardson, Paul
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S181 - S182
[7] Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Richardson, Paul
Sandhu, Irwindeep
Oriol, Albert
Raab, Marc S.
White, Darrell
LeBlanc, Richard
Perrot, Aurore
Ocio, Enrique
Raje, Noopur
Hansen, Charlotte Toftmann
Zhou, Zehua
Civardi, Tiziana
Ghiddi, Alessandro
Katz, Jessica
Peluso, Teresa
Dimopoulos, Meletios A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S33 - S33
[8] Initial results of phase 1/2 study CC-92480-MM-002 onCELMoD CC-92480 in combination with bortezomib (BORT)and dexamethasone (DEX) in patients with relapsed /refractory multiple myeloma (RRMM)
Raab, M. -S.
Richardson, P. G.
Ocio, E. M.
Raje, N.
Gregory, T.
White, D.
Oriol, A.
Sandhu, I.
LeBlanc, R.
Rodriguez Valdes, C.
Trudel, S.
Waesch, R.
Perrot, A.
Bahlis, N. J.
Zhou, Z.
Lamba, M.
Amatangelo, M.
Civardi, T.
Katz, J.
Maciag, P.
Peluso, T.
Dimopoulos, M. A.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 86 - 86
[9] Preliminary results from phase 2 of CC-92480-MM-001: Mezigdomide plus dexamethasone in relapsed/refractory multiple myeloma (RRMM)
Popat, Rakesh
Richardson, Paul G.
Trudel, Suzanne
Quach, Hang
Lonial, Sagar
Orlowski, Robert Z.
Kim, Kihyun
Mateos, Maria-Victoria
Pawlyn, Charlotte
Ramasamy, Karthik
Martinez-Lopez, Joaquin
Casas-Aviles, Ignacio
Spirli, Alessia
Gong, Jing
Amatangelo, Michael
Katz, Jessica
Maciag, Paulo
Peluso, Teresa
Bahlis, Nizar J.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 66 - 67
[10] Mezigdomide (MEZI), Tazemetostat (TAZ), and Dexamethasone (DEX) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results From the CA057-003 Trial
Costa, Luciano
Popat, Rakesh
Siegel, David
Schjesvold, Fredrik
Usmani, Saad
Bahlis, Nizar J.
Oriol, Albert
Chu, Michael
Ali, Syed Abbas
Ramasamy, Karthik
Hartley-Brown, Monique
Martinez-Lopez, Joaquin
Gaudy, Allison
Kurtova, Antonina
Zhang, Wen
Sarmiento, Rafael
Dietrich, August
Katz, Jessica
Pourdehnad, Michael
Richardson, Paul
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S19 - S19

← 1 2 3 4 5 →